PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview
PepGen Inc <PEPG.OQ> expected to post a loss of 29 cents a share - Earnings Preview
PepGen Inc PEPG.OQ PEPG.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for PepGen Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PepGen Inc is $10.50, about 496.6% above its last closing price of $1.76
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.32 | -0.31 | -0.26 | Beat | 16.7 |
Dec. 31 2026 | -0.40 | -0.37 | -0.27 | Beat | 27.9 |
Sep. 30 2025 | -0.60 | -0.56 | -0.52 | Beat | 8 |
Jun. 30 2025 | -0.83 | -0.83 | -0.70 | Beat | 15.4 |
Mar. 31 2025 | -0.71 | -0.72 | -0.92 | Missed | -27.8 |
Dec. 31 2024 | -0.80 | -0.81 | -0.68 | Beat | 16.1 |
Sep. 30 2024 | -0.86 | -0.87 | -0.66 | Beat | 24 |
Jun. 30 2024 | -0.71 | -0.72 | -0.87 | Missed | -20.5 |
This summary was machine generated August 3 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview